Adaptive Biotechnologies Corporation (ADPT) Stock Grade

About Adaptive Biotechnologies Corporation's fundamentals

Adaptive Biotechnologies is a biotech company with a market capitalization of $4.6 billion that is experiencing strong revenue expansion, growing at 54.8% year-over-year. However, the company is currently unprofitable, operating at a negative net margin of -21.5% and reporting a net loss in its latest annual statement. The company does not pay a dividend, which is typical for early-stage biotechnology firms focused on growth rather than shareholder distributions. Traditional profitability metrics like P/E ratio and return on equity are not applicable given the company's loss-making status.